Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 1
2017 1
2018 2
2020 1
2021 4
2022 3
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Results by year

Filters applied: . Clear all
Page 1
An Antigenic Thrift-Based Approach to Influenza Vaccine Design.
Bolton JS, Klim H, Wellens J, Edmans M, Obolski U, Thompson CP. Bolton JS, et al. Among authors: thompson cp. Vaccines (Basel). 2021 Jun 16;9(6):657. doi: 10.3390/vaccines9060657. Vaccines (Basel). 2021. PMID: 34208489 Free PMC article. Review.
Influenza vaccination and the 'diversity paradox'.
Thompson CP, Obolski U. Thompson CP, et al. Hum Vaccin Immunother. 2018;14(12):3005-3009. doi: 10.1080/21645515.2018.1504596. Epub 2018 Sep 21. Hum Vaccin Immunother. 2018. PMID: 30239261 Free PMC article.
Cellular immunity to SARS-CoV-2 following intrafamilial exposure in seronegative family members.
Jay C, Adland E, Csala A, Dold C, Edmans M, Hackstein CP, Jamsen A, Lim N, Longet S, Ogbe A, Sampson O, Skelly D, Spiller OB, Stafford L, Thompson CP, Turtle L, Barnes E, Dunachie S, Carroll M, Klenerman P, Conlon C, Goulder P, Jones LC. Jay C, et al. Among authors: thompson cp. Front Immunol. 2023 Aug 29;14:1248658. doi: 10.3389/fimmu.2023.1248658. eCollection 2023. Front Immunol. 2023. PMID: 37711627 Free PMC article.
Fatal COVID-19 outcomes are associated with an antibody response targeting epitopes shared with endemic coronaviruses.
McNaughton AL, Paton RS, Edmans M, Youngs J, Wellens J, Phalora P, Fyfe A, Belij-Rammerstorfer S, Bolton JS, Ball J, Carnell GW, Dejnirattisai W, Dold C, Eyre DW, Hopkins P, Howarth A, Kooblall K, Klim H, Leaver S, Lee LN, López-Camacho C, Lumley SF, Macallan DC, Mentzer AJ, Provine NM, Ratcliff J, Slon-Compos J, Skelly D, Stolle L, Supasa P, Temperton N, Walker C, Wang B, Wyncoll D; Oxford Protective T Cell Immunology for COVID-19 (OPTIC) consortium; Scottish National Blood Transfusion Service (SNBTS) consortium; Simmonds P, Lambe T, Baillie JK, Semple MG, Openshaw PJ; International Severe Acute Respiratory and emerging Infection Consortium Coronavirus Clinical Characterisation Consortium (ISARIC4C) investigators; Obolski U, Turner M, Carroll M, Mongkolsapaya J, Screaton G, Kennedy SH, Jarvis L, Barnes E, Dunachie S, Lourenço J, Matthews PC, Bicanic T, Klenerman P, Gupta S, Thompson CP. McNaughton AL, et al. Among authors: thompson cp. JCI Insight. 2022 Jul 8;7(13):e156372. doi: 10.1172/jci.insight.156372. JCI Insight. 2022. PMID: 35608920 Free PMC article.
Hypoxic and pharmacological activation of HIF inhibits SARS-CoV-2 infection of lung epithelial cells.
Wing PAC, Keeley TP, Zhuang X, Lee JY, Prange-Barczynska M, Tsukuda S, Morgan SB, Harding AC, Argles ILA, Kurlekar S, Noerenberg M, Thompson CP, Huang KA, Balfe P, Watashi K, Castello A, Hinks TSC, James W, Ratcliffe PJ, Davis I, Hodson EJ, Bishop T, McKeating JA. Wing PAC, et al. Among authors: thompson cp. Cell Rep. 2021 Apr 20;35(3):109020. doi: 10.1016/j.celrep.2021.109020. Epub 2021 Apr 5. Cell Rep. 2021. PMID: 33852916 Free PMC article.
Combination therapy of infliximab and thiopurines, but not monotherapy with infliximab or vedolizumab, is associated with attenuated IgA and neutralisation responses to SARS-CoV-2 in inflammatory bowel disease.
Wellens J, Edmans M, Obolski U, McGregor CG, Simmonds P, Turner M, Jarvis L, Skelly D, Dunachie S, Barnes E, Eyre DW, Colombel JF, Wong SY, Klenerman P, Lindsay JO, Satsangi J, Thompson CP. Wellens J, et al. Among authors: thompson cp. Gut. 2022 Sep;71(9):1919-1922. doi: 10.1136/gutjnl-2021-326312. Epub 2021 Dec 15. Gut. 2022. PMID: 34911744 No abstract available.
Identification of immune correlates of fatal outcomes in critically ill COVID-19 patients.
Youngs J, Provine NM, Lim N, Sharpe HR, Amini A, Chen YL, Luo J, Edmans MD, Zacharopoulou P, Chen W, Sampson O, Paton R, Hurt WJ, Duncan DA, McNaughton AL, Miao VN, Leaver S, Wyncoll DLA, Ball J, Hopkins P; Oxford Immunology Network Covid-19 response T cell Consortium; Oxford Protective T cell Immunology for COVID-19 (OPTIC) Clinical team; Skelly DT, Barnes E, Dunachie S, Ogg G, Lambe T, Pavord I, Shalek AK, Thompson CP, Xue L, Macallan DC, Goulder P, Klenerman P, Bicanic T. Youngs J, et al. Among authors: thompson cp. PLoS Pathog. 2021 Sep 16;17(9):e1009804. doi: 10.1371/journal.ppat.1009804. eCollection 2021 Sep. PLoS Pathog. 2021. PMID: 34529726 Free PMC article.
A naturally protective epitope of limited variability as an influenza vaccine target.
Thompson CP, Lourenço J, Walters AA, Obolski U, Edmans M, Palmer DS, Kooblall K, Carnell GW, O'Connor D, Bowden TA, Pybus OG, Pollard AJ, Temperton NJ, Lambe T, Gilbert SC, Gupta S. Thompson CP, et al. Nat Commun. 2018 Sep 21;9(1):3859. doi: 10.1038/s41467-018-06228-8. Nat Commun. 2018. PMID: 30242149 Free PMC article.
13 results